Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

 Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
VP Genomics and Computational Biology, Biogen
Sally's group provides in-vivo and in-vitro models, technologies and analytics to support the discovery and development from identification of new targets through to understanding genetic variability in drug response and patient stratification.. Sally is a passionate advocate of the value of human genetics to support early drug discovery and is an active champion of open innovation and collaboration in the field of genomic and contributes to and organizes events aimed at fostering a deeper interaction between academia and industry. Prior to joining Biogen in 2014, she was Head of Clinical Genetics and Bioinformatics at Pfizer. She gained a Ph.D. in Molecular Biology from the University of Manchester, UK. She began her academic career studying the genetic basis of rheumatoid arthritis, focusing on genomic analysis in the context of epidemiological studies.

Brought to you by